The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting
Open accessAbstract
The tumor microenvironment (TME) is a critical regulator of tumor growth, progression, and metastasis. Among the innate immune cells recruited to the tumor site, macrophages are the most abundant cell population and are present at all stages of tumor progression. They undergo M1/M2 polarization in response to signals derived from TME. M1 macrophages suppress tumor growth, while their M2 counterparts exert pro-tumoral effects by promoting tumor growth, angiogenesis, metastasis, and resistance to current therapies. Several subsets of the M2 phenotype have been observed, often denoted as M2a, M2b, M2c, and M2d. These are induced by different stimuli and differ in phenotypes as well as functions. In this review, we discuss the key features of each M2 subset, their implications in cancers, and highlight the strategies that are being developed to harness TAMs for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 4×
“For instance, IL-10 has not only been proven to be a potent antiinflammatory cytokine that can inhibit the production and functional activities of various pro-inflammatory cytokines [34], but also favors the differentiation of naïve T cells into Treg cells [66].”
BackgroundInfluentialThe chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“IL-10 prevents monocytes from differentiating to dendritic cells (DCs) and skews macrophage polarization [76].”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Macrophage activation and polarization
Martinez, F. O. (2008) · Frontiers in Bioscience · doi:10.2741/2692 · Cited by 3,160
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
Orecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 2×
“The location of TAMs within the TME was found to affect their ability to support versus restrain tumor progression [1].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Macrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
Ravetch, J. V., & Kinet, J. P. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.002325 · Cited by 1,229
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
The role of macrophage phenotype in vascularization of tissue engineering scaffolds
Spiller, K. L., Anfang, R. R., Spiller, K. J., Ng, J., Nakazawa, K. R., Daulton, J. W., & Vunjak-Novakovic, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.012 · Cited by 948 · cited 1×
“Additionally, M2c may support tumor growth by inducing angiogenesis as the M2c macrophages facilitated endothelial cell mobility and tube formation in vitro and in vivo [82,83].”
BackgroundM2b macrophage polarization and its roles in diseases
Wang, L.-X., Zhang, S.-X., Wu, H.-J., Rong, X.-L., & Guo, J. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru1018-378rr · Cited by 884
Biochemical and functional characterization of three activated macrophage populations
Edwards, J. P., Zhang, X., Frauwirth, K. A., & Mosser, D. M. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0406249 · Cited by 863
Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo
Jetten, N., Verbruggen, S., Gijbels, M. J., Post, M. J., De Winther, M. P. J., & Donners, M. M. P. C. (2014) · Angiogenesis · doi:10.1007/s10456-013-9381-6 · Cited by 839
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Van Dyken, S. J., & Locksley, R. M. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095906 · Cited by 714
The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.
Alon, R., Kassner, P. D., Carr, M. W., Finger, E. B., Hemler, M. E., & Springer, T. A. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1243 · Cited by 706
Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
Junttila, I. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00888 · Cited by 684
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 657
Zizzo, G., Hilliard, B. A., Monestier, M., & Cohen, P. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200662 · Cited by 646
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
A tumor-homing peptide with a targeting specificity related to lymphatic vessels
Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002) · Nature Medicine · doi:10.1038/nm720 · Cited by 498
Duluc, D., Delneste, Y., Tan, F., Moles, M.-P., Grimaud, L., Lenoir, J., Preisser, L., Anegon, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 491
Tap, W. D., Gelderblom, H., Palmerini, E., Desai, J., Bauer, S., Blay, J.-Y., Alcindor, T., Ganjoo, K., Martín-Broto, J., Ryan, C. W., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30764-0 · Cited by 482
Weng, Y.-S., Tseng, H.-Y., Chen, Y.-A., Shen, P.-C., Al Haq, A. T., Chen, L.-M., Tung, Y.-C., & Hsu, H.-L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0988-0 · Cited by 444
Fc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Jaynes, J. M., Sable, R., Ronzetti, M., Bautista, W., Knotts, Z., Abisoye-Ogunniyan, A., Li, D., Calvo, R., Dashnyam, M., Singh, A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax6337 · Cited by 413
Targeting selectins and selectin ligands in inflammation and cancer
Barthel, S. R., Gavino, J. D., Descheny, L., & Dimitroff, C. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.11.1473 · Cited by 395
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4
Hsu, L.-C., Mo Park, J., Zhang, K., Luo, J.-L., Maeda, S., Kaufman, R. J., Eckmann, L., Guiney, D. G., & Karin, M. (2004) · Nature · doi:10.1038/nature02405 · Cited by 357
Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression
Yuan, A., Hsiao, Y.-J., Chen, H.-Y., Chen, H.-W., Ho, C.-C., Chen, Y.-Y., Liu, Y.-C., Hong, T.-H., Yu, S.-L., Chen, J. J. W., et al. (2015) · Scientific Reports · doi:10.1038/srep14273 · Cited by 352
Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma
Fogal, V., Zhang, L., Krajewski, S., & Ruoslahti, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6752 · Cited by 346
Tedesco, S., De Majo, F., Kim, J., Trenti, A., Trevisi, L., Fadini, G. P., Bolego, C., Zandstra, P. W., Cignarella, A., & Vitiello, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00071 · Cited by 336
A novel phenotype for an activated macrophage: the type 2 activated macrophage
Anderson, C. F., & Mosser, D. M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.101 · Cited by 333
Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 329
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival
Cieslewicz, M., Tang, J., Yu, J. L., Cao, H., Zavaljevski, M., Motoyama, K., Lieber, A., Raines, E. W., & Pun, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312197110 · Cited by 314
Interleukin 10 Receptor Signaling
Shouval, D. S., Ouahed, J., Biswas, A., Goettel, J. A., Horwitz, B. H., Klein, C., Muise, A. M., & Snapper, S. B. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00005-5 · Cited by 304
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 304
Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C. E., Schledzewski, K., & Goerdt, S. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00885.x · Cited by 300
Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1128 · Cited by 291
Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation
Wettschureck, N., Strilic, B., & Offermanns, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00037.2018 · Cited by 286
Aharinejad, S., Paulus, P., Sioud, M., Hofmann, M., Zins, K., Schäfer, R., Stanley, E. R., & Abraham, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0961 · Cited by 281
Self-citationThrombospondins: from structure to therapeutics: Thrombospondins in cancer
Kazerounian, S., Yee, K. O., & Lawler, J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7486-z · Cited by 277
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
Laakkonen, P., Åkerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., & Ruoslahti, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403317101 · Cited by 275
Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases
Skytthe, M. K., Graversen, J. H., & Moestrup, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155497 · Cited by 261
Rey-Giraud, F., Hafner, M., & Ries, C. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042656 · Cited by 257
Fu, X.-L., Duan, W., Su, C.-Y., Mao, F.-Y., Lv, Y.-P., Teng, Y.-S., Yu, P.-W., Zhuang, Y., & Zhao, Y.-L. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2052-5 · Cited by 242 · cited 8×
“Most often, high levels of TAMs in the TME are associated with cancer progression, metastatic spread, poor treatment efficacy, and shorter survival in several cancer types such as lung cancer [2,3], breast cancer [4–7], hepatocellular carcinoma (HCC) [8], gastric cancer [9], and melanoma [10].”
BackgroundInfluentialEngineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Sloas, C., Gill, S., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 241
Baxter, E. W., Graham, A. E., Re, N. A., Carr, I. M., Robinson, J. I., Mackie, S. L., & Morgan, A. W. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.112721 · Cited by 234
Transtumoral targeting enabled by a novel neuropilin-binding peptide
Roth, L., Agemy, L., Kotamraju, V. R., Braun, G., Teesalu, T., Sugahara, K. N., Hamzah, J., & Ruoslahti, E. (2012) · Oncogene · doi:10.1038/onc.2011.537 · Cited by 231
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
Xu, J., Lin, H., Wu, G., Zhu, M., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760971 · Cited by 228
Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing
Lurier, E. B., Dalton, D., Dampier, W., Raman, P., Nassiri, S., Ferraro, N. M., Rajagopalan, R., Sarmady, M., & Spiller, K. L. (2017) · Immunobiology · doi:10.1016/j.imbio.2017.02.006 · Cited by 216
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0610-4 · Cited by 211
The Interleukin-10 Family of Cytokines and Their Role in the CNS
Burmeister, A. R., & Marriott, I. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00458 · Cited by 207
Rückerl, D., Jenkins, S. J., Laqtom, N. N., Gallagher, I. J., Sutherland, T. E., Duncan, S., Buck, A. H., & Allen, J. E. (2012) · Blood · doi:10.1182/blood-2012-02-408252 · Cited by 202
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer
Lin, L., Chen, Y.-S., Yao, Y.-D., Chen, J.-Q., Chen, J.-N., Huang, S.-Y., Zeng, Y.-J., Yao, H.-R., Zeng, S.-H., Fu, Y.-S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5325 · Cited by 198
Anti-inflammatory Mechanisms Triggered by Apoptotic Cells during Their Clearance
Szondy, Z., Sarang, Z., Kiss, B., Garabuczi, É., & Köröskényi, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00909 · Cited by 197
Das, S., Sarrou, E., Podgrabinska, S., Cassella, M., Mungamuri, S. K., Feirt, N., Gordon, R., Nagi, C. S., Wang, Y., Entenberg, D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20111627 · Cited by 195
Shiratori, H., Feinweber, C., Luckhardt, S., Linke, B., Resch, E., Geisslinger, G., Weigert, A., & Parnham, M. J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.027 · Cited by 192
Kim, B., Pang, H.-B., Kang, J., Park, J.-H., Ruoslahti, E., & Sailor, M. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04390-7 · Cited by 192
Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide
Scodeller, P., Simón-Gracia, L., Kopanchuk, S., Tobi, A., Kilk, K., Säälik, P., Kurm, K., Squadrito, M. L., Kotamraju, V. R., Rinken, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14709-x · Cited by 179
Macrophage biology and immunology: man is not a mouse
Schneemann, M., & Schoeden, G. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106702 · Cited by 176
Grimbert, P., Bouguermouh, S., Baba, N., Nakajima, T., Allakhverdi, Z., Braun, D., Saito, H., Rubio, M., Delespesse, G., & Sarfati, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3534 · Cited by 174
Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment
Lahmar, Q., Keirsse, J., Laoui, D., Movahedi, K., Overmeire, E. V., & Ginderachter, J. A. V. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.009 · Cited by 173
Spada, S., Tocci, A., Di Modugno, F., & Nisticò, P. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01908-8 · Cited by 172
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Alexandra, P., West, B. L., Marimuthu, A., Severson, P. L., Karlin, D. A., Dowlati, A., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919854238 · Cited by 169
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting
Hourani, T., Holden, J. A., Li, W., Lenzo, J. C., Hadjigol, S., & O’Brien-Simpson, N. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.788365 · Cited by 168
Novel Peptide Therapeutic Approaches for Cancer Treatment
Li, C. M., Haratipour, P., Lingeman, R. G., Perry, J. J. P., Gu, L., Hickey, R. J., & Malkas, L. H. (2021) · Cells · doi:10.3390/cells10112908 · Cited by 167
Yao, A., Liu, F., Chen, K., Tang, L., Liu, L., Zhang, K., Yu, C., Bian, G., Guo, H., Zheng, J., et al. (2014) · Neurotherapeutics · doi:10.1007/s13311-013-0254-x · Cited by 165
Shirey, K. A., Cole, L. E., Keegan, A. D., & Vogel, S. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4159 · Cited by 163
Type I IL-4Rs Selectively Activate IRS-2 to Induce Target Gene Expression in Macrophages
Heller, N. M., Qi, X., Junttila, I. S., Shirey, K. A., Vogel, S. N., Paul, W. E., & Keegan, A. D. (2008) · Science Signaling · doi:10.1126/scisignal.1164795 · Cited by 162
Targeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 161
Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages
Koscsó, B., Csóka, B., Kókai, E., Németh, Z. H., Pacher, P., Virág, L., Leibovich, S. J., & Haskó, G. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113043 · Cited by 160
Sironi, M., Martinez, F. O., D’Ambrosio, D., Gattorno, M., Polentarutti, N., Locati, M., Gregorio, A., Iellem, A., Cassatella, M. A., Van Damme, J., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1005586 · Cited by 158
Figueiredo, P., Lepland, A., Scodeller, P., Fontana, F., Torrieri, G., Tiboni, M., Shahbazi, M., Casettari, L., Kostiainen, M. A., Hirvonen, J. J., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.09.038 · Cited by 145
Zhang, B., Bailey, W. M., Braun, K. J., & Gensel, J. C. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.001 · Cited by 135
Fu, C., Jiang, L., Hao, S., Liu, Z., Ding, S., Zhang, W., Yang, X., & Li, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02638 · Cited by 129
IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor
Chen, L., Wang, S., Wang, Y., Zhang, W., Ma, K., Hu, C., Zhu, H., Liang, S., Liu, M., & Xu, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24734 · Cited by 127
Wang, H., Sun, Y., Zhou, X., Chen, C., Jiao, L., Li, W., Gou, S., Li, Y., Du, J., Chen, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000905 · Cited by 127
Hamzah, J., Kotamraju, V. R., Seo, J. W., Agemy, L., Fogal, V., Mahakian, L. M., Peters, D., Roth, L., Gagnon, M.-H., Ferrara, K. W., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104540108 · Cited by 122
Lefèvre, L., Galès, A., Olagnier, D. P., Bernad, J., Perez, L., Burcelin, R., Valentin, A., Auwerx, J. H., Pipy, B., & Coste, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012828 · Cited by 109
Little, A. C., Pathanjeli, P., Wu, Z., Bao, L., Goo, L., Yates, J. A., Oliver, C. R., Soellner, M. B., & Merajver, S. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00456 · Cited by 108
Liu, R., Yuan, W., Zeng, Q., Chan, K., Xiao, C., Zhao, X., Chen, M., Ouyang, F., Chen, D., Zheng, L., et al. (2015) · Hepatology · doi:10.1002/hep.28020 · Cited by 103
Lugo‐Villarino, G., Troegeler, A., Balboa, L., Lastrucci, C., Duval, C., Mercier, I., Bénard, A., Capilla, F., Saati, T. A., Poincloux, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01123 · Cited by 97
Hong, H.-Y., Lee, H. Y., Kwak, W., Yoo, J., Na, M., So, I. S., Kwon, T., Park, H., Huh, S., Oh, G. T., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00189.x · Cited by 96
Cho, U., Kim, B., Kim, S., Han, Y., & Song, Y. S. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22750 · Cited by 94
Tournaire, R., Simon, M., le Noble, F. A. C., Eichmann, A., England, P., & Pouysségur, J. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400100 · Cited by 91
Jeannin, P., Duluc, D., & Delneste, Y. (2011) · Immunotherapy · doi:10.2217/imt.11.30 · Cited by 84
In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages
Lum, H. D., Buhtoiarov, I. N., Schmidt, B. E., Berke, G., Paulnock, D. M., Sondel, P. M., & Rakhmilevich, A. L. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405191 · Cited by 81
Lee, C., Bae, S.-J. S., Joo, H., & Bae, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18627 · Cited by 79
Stromal cell‐derived CSF‐1 blockade prolongs xenograft survival of CSF‐1‐negative neuroblastoma
Abraham, D., Zins, K., Sioud, M., Lucas, T., Schäfer, R., Stanley, E. R., & Aharinejad, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24859 · Cited by 78
Self-citationLong‐term outcomes of pexidartinib in tenosynovial giant cell tumors
Gelderblom, H. A. J., Wagner, A. J., Tap, W. D., Palmerini, E., Wainberg, Z. A., Desai, J., Healey, J. H., van de Sande, M. A. J., Bernthal, N. M., Staals, E. L., et al. (2020) · Cancer · doi:10.1002/cncr.33312 · Cited by 71
Pang, L., Pei, Y., Uzunallı, G., Hyun, H., Lyle, L. T., & Yeo, Y. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2596-5 · Cited by 69
Andersen, M. N., Etzerodt, A., Graversen, J. H., Holthof, L. C., Moestrup, S. K., Hokland, M., & Møller, H. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02301-3 · Cited by 66
Recent progress in LyP-1-based strategies for targeted imaging and therapy
Song, N., Zhao, L., Zhu, M., & Zhao, J. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1587047 · Cited by 66
Ohlsson, S. M., Linge, P., Gullstrand, B., Lood, C., Johansson, Å. C. M., Ohlsson, S., Lundqvist, A., Bengtsson, A. A., Carlsson, F., & Hellmark, T. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.02.016 · Cited by 65
Liu, Y., Ji, X., Kang, N., Zhou, J., Liang, X. Y., Li, J., Han, T., Zhao, C., & Yang, T. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03161-x · Cited by 65
Regulation of macrophage phenotype by long-term exposure to IL-10
Park‐Min, K., Antoniv, T. T., & Ivashkiv, L. B. (2005) · Immunobiology · doi:10.1016/j.imbio.2005.05.002 · Cited by 64
Maeda, A., Digifico, E., Andon, F. T., Mantovani, A., & Allavena, P. (2019) · European Journal of Immunology · doi:10.1002/eji.201847888 · Cited by 64
Zhou, W., Du, W.-D., Li, Y.-F., Al‐Aroomi, M. A., Yan, C., Wang, Y., Zhang, Z., Liu, F., & Sun, C.-F. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s364708 · Cited by 63
Allavena, P., Anfray, C., Ummarino, A., & Torres, F. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1679 · Cited by 58
Zhang, L., Qi, Y., Min, H., Chen, N., Wang, F., Wang, B., Qin, H., Zhang, Y., Liu, G., Qin, Y., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08142 · Cited by 56
CCL1 released from M2b macrophages is essentially required for the maintenance of their properties
Asai, A., Nakamura, K., Kobayashi, M., Herndon, D. N., & Suzuki, F. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212107 · Cited by 54
Macrophage Polarization in IL-10 Treatment of Particle-Induced Inflammation and Osteolysis
Jiang, J., Jia, T., Gong, W., Ning, B., Wooley, P. H., & Yang, S. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.09.006 · Cited by 53
Zhang, L., Zhang, C., Xing, Z., Lou, C., Fang, J., Wang, Z. P., Li, M., He, H., & Bai, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109420 · Cited by 51
Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer
Hung, C., Chen, F., Lin, Y.-C., Tsai, M.-L., Wang, S.-L., Chen, Y., Chen, Y., & Hou, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4284-y · Cited by 50
Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep)
Ngambenjawong, C., Gustafson, H. H., Pineda, J. M., Kacherovsky, N. A., Cieslewicz, M., & Pun, S. H. (2016) · Theranostics · doi:10.7150/thno.15394 · Cited by 49
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Martín-Otal, C., Lasarte-Cía, A., Serrano, D., Casares, N., Conde, E., Navarro, F. C., Sánchez-Moreno, I., Gorraiz, M., Sarrión, P., Calvo, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004479 · Cited by 49
Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000. 164: 6166–6173
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701141 · Cited by 48
Identification of TAX2 peptide as a new unpredicted anti-cancer agent
Jeanne, A., Sick, É., Devy, J., Floquet, N., Belloy, N., Thérêt, L., Boulagnon‐Rombi, C., Diébold, M.-D., Dauchez, M., Martiny, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4025 · Cited by 47
Tumor-specific macrophage targeting through recognition of retinoid X receptor beta
Tang, T., Wei, Y., Kang, J., She, Z., Kim, D., Sailor, M. J., Ruoslahti, E. I., & Pang, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.009 · Cited by 47
CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model
Wang, Q., Sudan, K., Schmoeckel, E., Kost, B. P., Kühn, C., Vattai, A., Vilsmaier, T., Mahner, S., Jeschke, U., & Heidegger, H. H. (2022) · Cells · doi:10.3390/cells11132027 · Cited by 45
Homing Peptides for Cancer Therapy
Lingasamy, P., & Teesalu, T. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_2 · Cited by 43
Asai, A., Tsuchimoto, Y., Ohama, H., Fukunishi, S., Tsuda, Y., Kobayashi, M., Higuchi, K., & Suzuki, F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299301 · Cited by 42
Lepland, A., Asciutto, E. K., Malfanti, A., Simón‐Gracia, L., Sidorenko, V., Vicent, M. J., Teesalu, T., & Scodeller, P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00226 · Cited by 42
Schepisi, G., Gianni, C., Palleschi, M., Bleve, S., Casadei, C., Lolli, C., Ridolfi, L., Martinelli, G., & Giorgi, U. D. (2023) · Cancers · doi:10.3390/cancers15051597 · Cited by 41
Vadevoo, S. M. P., Kim, J., Gunassekaran, G. R., Jung, H.-K., Chi, L., Kim, D. E., Lee, S., Im, S., & Lee, B.-H. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0339 · Cited by 40
M2b macrophage polarization accompanied with reduction of long noncoding RNA GAS5
Ito, I., Asai, A., Suzuki, S., Kobayashi, M., & Suzuki, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.053 · Cited by 40
Engineering an Affinity-Enhanced Peptide through Optimization of Cyclization Chemistry
Ngambenjawong, C., Pineda, J. M. B., & Pun, S. H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00502 · Cited by 37
Granulin Exacerbates Lupus Nephritis via Enhancing Macrophage M2b Polarization
Chen, X., Wen, Z., Xu, W., & Xiong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065542 · Cited by 36
Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity
Jeanne, A., Sarazin, T., Charlé, M., Moali, C., Fichel, C., Boulagnon‐Rombi, C., Callewaert, M., Andry, M. C., Diesis, É., Delolme, F., et al. (2021) · Cancers · doi:10.3390/cancers13195019 · Cited by 36
Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Meyer, I. D., Martinet, W., & Meyer, G. R. Y. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04211.x · Cited by 35
Macrophages and Metabolic Reprograming in the Tumor Microenvironment
Liu, J., Gao, M., Zhou, Y., Zhao, Y. D., Guo, K., Sun, B., Gao, Z., & Wang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.795159 · Cited by 34
Kim, D., Koh, J., Ko, J. S., Kim, H. Y., Lee, H., & Chung, D. H. (2019) · Immune Network · doi:10.4110/in.2019.19.e32 · Cited by 33
Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque
She, Z., Hamzah, J., Kotamraju, V. R., Pang, H., Jansen, S. J., & Ruoslahti, E. I. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.020 · Cited by 29
Selective targeting of tumor associated macrophages in different tumor models
Kakoschky, B., Pleli, T., Schmithals, C., Zeuzem, S., Brüne, B., Vogl, T. J., Korf, H., Weigert, A., & Piiper, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193015 · Cited by 29
Ailuno, G., Baldassari, S., Zuccari, G., Schlich, M., & Caviglioli, G. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101461 · Cited by 28
A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells
Sioud, M., Skorstad, G., Mobergslien, A., & Sæbøe‐Larssen, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-224758 · Cited by 27
Self-citationAsciutto, E. K., Kopanchuk, S., Lepland, A., Simón‐Gracia, L., Alemán, C., Teesalu, T., & Scodeller, P. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b11876 · Cited by 27
Therapeutic Effect of Melittin–dKLA Targeting Tumor-Associated Macrophages in Melanoma
Han, I., Jeong, C., Yang, J., Park, S., Hwang, D., & Bae, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063094 · Cited by 27
Chen, Z., Dong, F., Lu, J., Wei, L., Tian, L., Ge, H., Zou, Y., Ma, X., Yang, Y., Zhou, L., et al. (2018) · Immunobiology · doi:10.1016/j.imbio.2018.08.008 · Cited by 20
Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages
Santos, M. A. R. D. C., dos Reis, J. S., Santos, C. A. D. N., da Costa, K. M., Barcelos, P. M., Francisco, K. Q. D. O., Barbosa, P. A. G. N., da Silva, E. D. S., Freire-de-Lima, C. G., Morrot, A., et al. (2022) · Immunologic Research · doi:10.1007/s12026-022-09321-9 · Cited by 20
Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment
Zhou, X., Chen, B., Zhang, Z., Huang, Y., Li, J., Wei, Q., Cao, D., & Ai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113258 · Cited by 19
Patik, I., Redhu, N. S., Eran, A., Bao, B., Nandy, A., Tang, Y., Sayed, S. E., Shen, Z., Glickman, J. N., Fox, J. G., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.02.006 · Cited by 18
Ito, I., Bhopale, K. K., Nishiguchi, T., Lee, J. O., Herndon, D. N., Suzuki, S., Sowers, L. C., Suzuki, F., & Kobayashi, M. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0617 · Cited by 17
Modulating the Tumor Microenvironment with RNA Interference as a Cancer Treatment Strategy
Zins, K., Sioud, M., Aharinejad, S., Lucas, T., & Abraham, D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1538-5_9 · Cited by 14
Self-citationTargeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Sioud, M., Pettersen, S., Ailte, I., & Fløisand, Y. (2019) · Cancers · doi:10.3390/cancers11081088 · Cited by 12
Self-citationZhang, Q., Olberg, A., & Sioud, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084282 · Cited by 9
Self-citation
Cited by
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Macrophage plasticity: signaling pathways, tissue repair, and regeneration
Yan, L., Wang, J., Cai, X., Liou, Y., Shen, H., Hao, J., Huang, C., Luo, G., & He, W. (2024) · MedComm · doi:10.1002/mco2.658 · Cited by 343
Metadata
- Authors
- Zhang, Q., & Sioud, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-04-19
- Volume
- 24
- Issue
- 8
- Pages
- 7493
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4366417608
- Cited by
- 300
- References
- 150
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.